Würzburg, Germany – July 31, 2025
Mondego Bio today announced preliminary safety and efficacy results for its leading PTPN2 inhibitor, ZE00-0388, presented at the EMBO Workshop Phosphatases: From Basic Research to Translation (July 27–31, 2025, Würzburg, Germany).
The company confirmed on-target modulation of the JAK-STAT pathway and stimulation of IFNγ release in human PBMCs by its lead compounds. ZE00-0388 also demonstrated strong oral bioavailability and significant efficacy when combined with anti–mPD-1 therapy in subcutaneous MC38 colon cancer models in female C57BL/6 mice.
The combination therapy not only halted tumor growth but also induced complete and sustained tumor regression, even after discontinuation of anti–mPD-1 treatment. Across all tested doses, Mondego’s lead compounds showed favorable safety and tolerability profiles.
“These data highlight the potential of ZE00-0388 and our PTPN2 inhibitor program to advance immuno-oncology therapies,” said Sanja Baumann-Tomovska, PhD Mondego Head of BD&L
